Insider Transactions in Q1 2022 at Eagle Pharmaceuticals, Inc. (EGRX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2022
|
Scott Tarriff |
BUY
Grant, award, or other acquisition
|
Direct |
34,800
+2.16%
|
-
|
|
Feb 28
2022
|
Brian Joseph Cahill CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+19.67%
|
-
|
|
Feb 28
2022
|
Michael Shawn Moran EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,400
+24.46%
|
-
|
|
Feb 02
2022
|
Michael Shawn Moran EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
742
-3.3%
|
$33,390
$45.03 P/Share
|
|
Feb 02
2022
|
Brian Joseph Cahill CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
805
-3.16%
|
$36,225
$45.03 P/Share
|
|
Jan 31
2022
|
Brian Joseph Cahill CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
626
-2.4%
|
$28,170
$45.94 P/Share
|
|
Jan 31
2022
|
Michael Shawn Moran EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
210
-0.93%
|
$9,450
$45.94 P/Share
|
|
Jan 07
2022
|
Brian Joseph Cahill CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
263
-1.0%
|
$13,150
$50.63 P/Share
|
|
Jan 07
2022
|
Michael Shawn Moran EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
90
-0.4%
|
$4,500
$50.63 P/Share
|
|
Jan 05
2022
|
Brian Joseph Cahill CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
738
-2.72%
|
$36,900
$50.69 P/Share
|
|
Jan 05
2022
|
Michael Shawn Moran EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,511
-6.23%
|
$75,550
$50.69 P/Share
|